HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Jonathan Hammond Kenneth W. Jeleniowski Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Coleman, C. I. Articles by White, C. M. Search for Related Content PubMed PubMed Citation Articles by Coleman, C. I. Articles by White, C. M. Related Collections Cardiac - physiology Cardiac - other Coronary disease

J Thorac Cardiovasc Surg 2007;133:1547-1552
© 2007 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology

Evaluating the safety implications of aprotinin use: The Retrospective Evaluation of Aprotinin in Cardio Thoracic Surgery (REACTS)

^a Division of Cardiology, Hartford Hospital, Hartford, Conn
^b Division of Cardiothoracic Surgery, Hartford Hospital, Hartford, Conn
^c The University of Connecticut School of Pharmacy, Storrs and Farmington, Conn
^d The University of Connecticut School of Medicine, Storrs and Farmington, Conn

Received for publication October 20, 2006; revisions received January 3, 2007; accepted for publication January 8, 2007.

^_* Address for reprints: C. Michael White, PharmD, FCCP, FCP, Director, Cardiac Pharmacology Service, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102-5037. (Email: cmwhite{at}harthosp.org).

Objectives: Aprotinin is a drug used to reduce bleeding in patients undergoing cardiothoracic surgery with cardiopulmonary bypass. A recent cohort evaluation found elevated risks of renal, cardiovascular, and cerebrovascular events when aprotinin was used. We sought to determine the impact of aprotinin on safety variables among patients receiving cardiothoracic surgery with cardiopulmonary bypass from a single US hospital that reserves aprotinin for complex surgeries and Jehovah’s Witnesses and does not utilize celite-based activated clotting time determinations.

Methods: We performed a cohort evaluation with multivariate logistic regression, including propensity score adjustment comprising patients from January 1, 2000 and December 31, 2005. We evaluated 3348 patients having cardiothoracic surgery in a single tertiary care medical center. We observed aprotinin use or lack of aprotinin in cardiothoracic surgery. The main outcome measures were odds (expressed as an odds ratio with 95% confidence interval) of developing myocardial infarction, cerebrovascular events, and renal dysfunction after cardiothoracic surgery between groups.

Results: Patients receiving aprotinin were less likely to experience a cerebrovascular event compared with control [0.65 (0.46–0.91)] and did not have an elevated odds of myocardial infarction [1.04 (0.53–2.04)] but were more likely to experience postoperative renal dysfunction [2.03 (1.37–3.01)].

Conclusions: Aprotinin was not associated with negative myocardial or cerebrovascular risks but did increase the risk of renal dysfunction. It is not known whether the renal dysfunction reflects renal damage or a transient reduction in glomerular filtration pressure.

This article has been cited by other articles:

				A. Levrat, A. Gros, L. Rugeri, K. Inaba, B. Floccard, C. Negrier, and J.-S. David Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients Br. J. Anaesth., June 1, 2008; 100(6): 792 - 797. [Abstract] [Full Text] [PDF]